According to the Report, the Size of the Lyme Disease Diagnostics Market in Europe was valued at USD xx Million in 2022. It is anticipated to reach a CAGR of xx%, to reach USD xx Million by 2027, during the forecast period 2022 to 2027.
The rise in the incidence of Lyme disease and increased investments from government agencies and large corporations in the development of diagnostic kits are driving the European Lyme disease diagnostics market. If successful, developing a novel cytokine-based immunoassay for Lyme disease diagnostics could lead to earlier and faster identification of the condition. In addition, a book, a rapid point-of-care Lyme diagnostic test based on lateral flow technology, is being developed by researchers.
This research will likely contribute to new techniques for detecting Lyme disease and earlier diagnosis, accurate disease staging, and signs of successful therapy. Lyme disease diagnostics look for Borrelia immunizers in the blood or cerebrospinal fluid (CSF) to diagnose central nervous system disease symptoms.
Furthermore, Lyme disease misdiagnosis and delays in diagnosis can result in bacterial spread and involvement of distant organ systems, most notably the neurologic, cardiac, and musculoskeletal systems. Meningitis cranial nerve palsy is a common neurologic association symptom that develops after untreated infection. Several prominent companies have expanded their Lyme disease diagnostics portfolios in response to the approval, offering novel Lyme disease diagnostics.
T2 Biosystems created the T2Lyme Panel diagnostic technology for detecting germs that cause Lyme disease. As a result of these improvements, demand for improved Lyme disease diagnostics is expected to increase, propelling the Lyme disease diagnostics market ahead.
Lyme disease is a challenging medical condition to diagnose because of the growing number of tick-borne infectious diseases, the advent of new vector-borne diseases, and the complexity and variability of symptoms in each patient. In addition, there aren't enough investors to create remarkable diagnostic technologies for identifying Lyme disease, which limits the market's potential growth.
This research report on the Europe Lyme Disease Diagnostic Market has been segmented and sub-segmented into the following categories.
By Diagnostic tests:
By Diagnostic Technologies:
By End User:
By Country:
Geographically, Europe has a widespread disorder, and hence the market for Lyme disease diagnostics is expected to grow at a high in the future. It is likely to be driven by a rise in the incidence of Lyme disease over the next few years. In addition, the number of infections in the region has continuously climbed over the last two decades is likely to boost the market in Europe during the forecast period. Furthermore, the increase in the number of contaminated patients in Europe means that the demand for Lyme disease diagnostics is predicted to rise rapidly.
The German Lyme disease diagnostic market and U.K Lyme disease diagnostic market have a steady growth in these countries during the predicted period.
With technological innovation, the market is witnessing the development of novel diagnostic tests. These new diagnostic techniques could aid in the proper diagnosis of Lyme disease. The pattern separates early Lyme disease from the other disorders studied. Therefore, it can be used to accurately diagnose the condition even in clinical samples that had previously tested negative by the immunologic assay. Lyme disease is commonly treated with antibiotics. It can help you heal faster and more thoroughly if you start treatment early.
KEY MARKET PLAYERS
Prominent Companies dominating the Europe Lyme Disease Diagnostics Market Profiled in the Report are Boulder Diagnostics, Immunetics Inc, Covance Inc, Affymetrix Inc, Siemens AG, Baxter International Inc, Fresenius Medical Care AG & Co, Bio-Rad Laboratories, Alere Inc (ALR), Graphene Frontiers, Roche Diagnostics International Ltd, GlaxoSmithKline Pharmaceuticals Ltd.,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region